Shapiro GI - Search Results

1

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK. Ji H, et al. Among authors: shapiro gi. Cancer Cell. 2006 Jun;9(6):485-95. doi: 10.1016/j.ccr.2006.04.022. Epub 2006 May 25. Cancer Cell. 2006. PMID: 16730237 Free article.

2

Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.

Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ. Salgia R, et al. Among authors: shapiro gi. Oncogene. 1999 Jan 7;18(1):67-77. doi: 10.1038/sj.onc.1202273. Oncogene. 1999. PMID: 9926921

3

Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.

Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. Shapiro GI, et al. Clin Cancer Res. 1999 Oct;5(10):2925-38. Clin Cancer Res. 1999. PMID: 10537362

4

A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ Jr, Rollins BJ. Shapiro GI, et al. Clin Cancer Res. 2001 Jun;7(6):1590-9. Clin Cancer Res. 2001. PMID: 11410495 Clinical Trial.

5

A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.

Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ. Fidias P, et al. Clin Cancer Res. 2001 Dec;7(12):3942-9. Clin Cancer Res. 2001. PMID: 11751486 Clinical Trial.

6

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. Maulik G, et al. Among authors: shapiro gi. Clin Cancer Res. 2002 Feb;8(2):620-7. Clin Cancer Res. 2002. PMID: 11839685

7

Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.

Matranga CB, Shapiro GI. Matranga CB, et al. Among authors: shapiro gi. Cancer Res. 2002 Mar 15;62(6):1707-17. Cancer Res. 2002. PMID: 11912144

8

Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.

Jiang J, Matranga CB, Cai D, Latham VM Jr, Zhang X, Lowell AM, Martelli F, Shapiro GI. Jiang J, et al. Among authors: shapiro gi. Cancer Res. 2003 Nov 1;63(21):7410-22. Cancer Res. 2003. PMID: 14612540

9

Novel agents in the treatment of lung cancer: conference summary statement.

Lynch TJ, Adjei AA, Bunn PA Jr, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Lynch TJ, et al. Among authors: shapiro gi. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4199s-4204s. doi: 10.1158/1078-0432.CCR-040021. Clin Cancer Res. 2004. PMID: 15217958 No abstract available.

10

Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

Goffin JR, Anderson IC, Supko JG, Eder JP Jr, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT. Goffin JR, et al. Among authors: shapiro gi. Clin Cancer Res. 2005 May 1;11(9):3417-24. doi: 10.1158/1078-0432.CCR-04-2144. Clin Cancer Res. 2005. PMID: 15867243 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page